🇺🇸 FDA
Patent

US 12351625

Therapeutic antibodies against osteopontin

granted A61KA61K31/397A61K31/4184

Quick answer

US patent 12351625 (Therapeutic antibodies against osteopontin) held by United States Government as represented by the Department of Veterans Affairs expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/397, A61K31/4184, A61K31/519, A61K47/00